Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

Abstract Purpose of Review There have been significant advances in the treatment of
relapsed/refractory chronic lymphocytic leukemia (CLL) over the past two decades …

Opinion statement At the end of the 1990s, with the advent of imatinib for chronic myeloid
leukemia and rituximab for B cell lymphoproliferative diseases with CD20 expression, there …

Introduction: Despite recent advances in diagnosis, prognostication, and treatment options,
chronic lymphocytic leukemia (CLL) is still a largely incurable disease. New concepts on …

Mutation-selective drugs constitute a great advancement in personalized anticancer
treatment with increased quality of life and overall survival in cancers. However, the high …

Currently available treatment approaches for CLL offer the opportunity to individualize
therapy for every single patient with CLL. Inhibitors of B-cell receptor (BCR) signalling …

Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune hemolytic
anemia and immune thrombocytopenia and, less frequently, with pure red cell aplasia and …

Background While the efficacy and safety of zanubrutinib have been established in relapsed
or refractory chronic lymphocytic leukemia, the evidence on cost effectiveness is still lacking …

Introduction: Despite recent advances in diagnosis, prognostication, and treatment options,
chronic lymphocytic leukemia (CLL) is still a largely incurable disease. New concepts on …

L'auteur a étudié la prise en charge de 46 patients traités par le protocole RFC et 30 patients
par le RB suivis au service d'hématologie du CHU de Sétif sur une période allant de 2014 à …